Biotech Acquisition Co: Nasdaq/NYSE listing notice — Biotech Acquisition receives Nasdaq deficiency notice for missed annual meeting

Biotech Acquisition Co

Received Nasdaq notice on Jan 9, 2023 for failing to hold annual meeting for FY ended Dec 31, 2021.
Company must submit a plan to regain compliance by Feb 23, 2023.
If plan accepted, Nasdaq may grant extension until June 29, 2023 to comply.
Deficiency notice has no immediate effect on listing or trading.
Company intends to submit a compliance plan within required timeframe.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Biotech Acquisition Co received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: shareholders
Rules: 5620(a)

Exact text from the filing

January 9, 2023, Biotech Acquisition Company (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the Company’s failure to hold an annual meeting of shareholders for the fiscal year ended December 31, 2021. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market. The Notice states that the Com

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-23-002153

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.